

Help Us Improve Safety Info on IBD Medications

Better Safety Info in Pregnancy Starts with Your Referral

Gastroenterologists need more information on the safety of medications when used in pregnancy. MotherToBaby Pregnancy Studies has over 20 years of experience conducting pregnancy exposure cohort studies. With your patient referrals, our research will produce the scientific evidence you and your patients need to weigh the risks and benefits of given treatments for both mom and baby, allowing you to make informed decisions that minimize maternal and fetal/infant risk.

Rigorously Designed Research Studies

We partner with physicians and patients to monitor pregnancy exposure to gastrointestinal medications. Our strong cohort study design allows our team to tease apart risks that may be associated with underlying disease versus those associated with a medication exposure.

Please consider referring your patients if they fall into either of these two groups:

- Patients who have taken any of the following **medications** during a current pregnancy:
- Certolizumab (Cimzia®)
- Prucalopride (Motegrity®) study is also recruiting lactating patients
- Tofacitinib (Xeljanz®)
- 2. Patients who have **Crohn's disease, functional constipation** or **ulcerative colitis** and have not taken the above medications during pregnancy.

Learn More



Questions? Call 866.626.6847 | Text 855.999.3525 | Email or Chat at MotherToBaby.org.

Disclaimer: MotherToBaby Fact Sheets are meant for general information purposes and should not replace the advice of your health care provider.

MotherToBaby is a service of the non-profit Organization of Teratology Information Specialists (OTIS). OTIS/MotherToBaby encourages inclusive and person-centered language. While our name still contains a reference to mothers, we are updating our resources with more inclusive terms. Use of the term mother or maternal refers to a person who is pregnant. Use of the term father or paternal refers to a person who contributes sperm. Copyright by OTIS, January 7, 2022.